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ABSTRACT: Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid protein
hormone, with key impact on growth, development, and lifespan. The physiological and
clinical importance of IGF-1 prompted challenging chemical and biological trials toward the
development of its analogs as molecular tools for the IGF-1 receptor (IGF1-R) studies and as
new therapeutics. Here, we report a new method for the total chemical synthesis of IGF-1
analogs, which entails the solid-phase synthesis of two IGF-1 precursor chains that is
followed by the CuI-catalyzed azide−alkyne cycloaddition ligation and by biomimetic
formation of a native pattern of disulﬁdes. The connection of the two IGF-1 precursor chains
by the triazole-containing moieties, and variation of its neighboring sequences (Arg36 and
Arg37), was tolerated in IGF-1R binding and its activation. These new synthetic IGF-1
analogs are unique examples of disulﬁde bonds’ rich proteins with intra main-chain triazole
links. The methodology reported here also presents a convenient synthetic platform for the
design and production of new analogs of this important human hormone with non-standard
protein modiﬁcations.
■ INTRODUCTION
Human insulin and related insulin-like growth factors 1 and 2
(IGF-1 and IGF-2) are small protein hormones, with a key
impact on basal metabolism, growth, development,1−3 life-
span,4,5 as well as being implicated in diabetes and cancer.6,7
Hence their central biological importance and involvement in
many relevant human pathologies require eﬀorts toward the
development of speciﬁc analogs of these hormones for studies
of the interactions and signaling with respective insulin- and
IGF-receptors (IR, IGF-1R) and their applications as new
therapeutics.3−9 The recombinant production of insulin and
IGFs in E. coli, or in yeast, was an obvious choice,10−12 but did
not easily allow the incorporation of non-coded amino acids
and unusual structural motifs, which could facilitate more
directed structure−activity studies of the hormones and their
rational modiﬁcations. Moreover, the total chemical synthesis
of these proteins, especially of IGF-1 and -2, remains a very
challenging task.13
The single-chain organization, fold, and disulﬁde bond
pattern of IGF-1/IGF-2 is similar to proinsulin, a prohormone
of insulin, but they are signiﬁcantly longer (70, 67, and 86
residues, respectively) than both insulin chains (21 and 30
amino acids). Therefore, their solid-phase synthesis is
challenging and ineﬃcient as demonstrated by only few early
reports on the total chemical synthesis of IGF-1 analogs.14−16
Nevertheless, elegant studies employed a combination of
shorter protein fragments by a native ligation for the synthesis
of human proinsulin,17 single chain “ester” insulin,18,19 and
IGF-1 analog.20 The complexity of the synthesis of these
hormones is highlighted further by only one report on the total
chemical synthesis of IGF-2.21
Therefore, our aim here was to develop a new methodology
for the chemical synthesis of IGF-1 analogs as a feasible
alternative for the production of single-chain insulin-like
hormones, and one that would allow easy incorporation of
non-standard amino acids or other unusual structural motifs.
As the solid-phase synthesis of a single, 70-amino acid chain
of IGF-1 is ineﬃcient, in this work we combined the solid-
phase synthesis of two shorter precursor IGF-1 fragments with
their ligation by a CuI-catalyzed 1,3-dipolar cycloaddition of
azides and alkynes,22−24 followed by the biomimetic formation
of the native pattern of disulﬁde bridges. CuI-catalyzed 1,3-
dipolar cycloaddition of azides and alkynes is a biorthogonal
reaction, also called a “click” chemistry, which leads to the
formation of 1,4-disubstituted 1,2,3-triazoles. This reaction has
become widely used25 in organic, medicinal, and, especially,
peptide chemistry,26 as 1,2,3-triazole is a motif with the
structural and electronic characteristics similar to those of the
peptide bond.27,28
The synthesis of insulin and insulin-like proteins is diﬃcult
due to the necessity to form three disulﬁde bridges. Therefore,
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a number of sophisticated methods of insulin synthesis have
been developed, usually with an orthogonal protection of
cysteines (e.g., in refs 29 and 30 and reviewed in ref 31) and a
directed, stepwise formation of disulﬁdes. A similar strategy was
developed for other proteins from the insulin family, such as
relaxins, DILP, INSL peptides,32−36 and cone snail insulin.37 An
alternative, and straightforward, method for the formation of
disulﬁdes starts with the simultaneous deprotection of all six
cysteines (from e.g. S-sulfonate protected forms) and pairing by
a slow air oxidation. This approach takes advantage of the
intrinsic biomimetic ability of insulin chains to adopt a natural
conformation and a correct coupling of disulﬁdes.18,38−43 In
this study, we used the strategy of biomimetic formation of
disulﬁdes for the synthesis of IGF-1 analogs.
The biological functionality aspect of this work was focused
on the role and modiﬁcations of the IGF-1 C domain,
speciﬁcally, at its Arg36 and Arg37 sites. The C domain of IGF-
1 (residues 30−41, Figure 1) was found to be important for its
functionality,44−46 as the double Arg36-Arg37 → Ala36-Ala37
mutation severely impaired binding of this mutant to the IGF-1
receptor (IGF-1R)47 and to IGF binding protein 1 (IGFBP-1),
which contributes to the regulation of IGF-1 bioavailability.48
In addition, a double Arg36-Arg37→ Glu36-Glu37 substitution
also indicated a partial antagonism of this analog, that is, its still
eﬀective binding to IGF-1R, but an impaired receptor
signaling49 and tumorigenesis.50
Interestingly, the connectivity, that is, well-deﬁned electron
density for residues Arg36- Arg37-Ala38, and, generally, for this
central part of the C domain, was frequently missing in several
crystal structures of human free, and IGFBP-bound, IGF-1
(Figure 1).51−53 It was postulated then that the pair of these
basic arginine side chains may constitute an in vivo proteolytic
cleavage site. Although the presence of Arg36 and Arg37 in the
IGF-1 C domain is important for an eﬃcient binding to IGF-
1R,47 it was not known whether the cleavage of the Arg36-
Arg37 peptide bond impairs hormone binding to IGF-1R or if
the resulting two-chain IGF-1 is still able to eﬀectively activate
IGF-1R. For this reason, we produced a two-chain IGF-1
analog here as well, which is disconnected between sites Arg36
and Arg37.
Together, we designed, synthesized, and characterized one
two-chain IGF-1 analog and three single-chain IGF-1 analogs
with a connecting triazole bridge between, or in, sites 36 and 37
to probe the feasibility of their synthesis and to test the impact
of these modiﬁcations on the biological activities of these
analogs. In one of the analogs, Met59 was mutated to Nle59 to
prevent oxidation of Met. The in vitro functional properties of
the analogs were characterized by the determination of their
binding aﬃnities to the IGF-1R, insulin receptor isoform A (IR-
A), and their receptor-activation potencies. The IR-A receptor
was used here as an IR isoform that, in contrast to its IR-B
isoform, is a relatively good binder of IGF-1 and, especially, of
IGF-2.12,54,55
■ RESULTS
Synthesis. The primary structures of peptide precursors and
analogs are shown in Figure 2, and the respective synthetic
pathways are overviewed in the Supporting Information Figures
S1−S4.
Two-Chain IGF-1 Analog. First, a two-chain human IGF-1
was prepared, referred to as analog 1, which has a native IGF-1
amino acid sequence, with the same pattern of the disulﬁde
bonds, but it has a split Arg36-Arg37 peptide bond. Hence,
analog 1 consists of chain 1-36 and chain 37-70, with all N-
termini and C-termini being in the free amine or carboxylic acid
forms, respectively (Figure 2).
The individual chains of the analog were prepared by a
standard solid-phase synthesis, and the free SH groups of
cysteines were converted to S-sulfonates (chains 1a and 1b,
Figure 2) immediately after the cleavage of Trt protecting
groups (Figure S1). The chains were recombined (i.e.,
disulﬁdes formed) to give analog 1 with approximately 0.6%
yield (0.2 mg) by a procedure described previously.42,43
Single-Chain IGF-1 Analogs. We designed the strategy of
the solid-phase peptide synthesis of two shorter IGF-1 chains
with β-azido-alanine or propargyl glycine at their C- or N-
termini, respectively, followed by their ligation by the CuI-
catalyzed azide−alkyne cycloaddition.22−24 The ﬁnal synthetic
step consisted of the simultaneous biomimetic formation of the
native pattern of all three disulﬁde bridges, as in analog 1.
The analog 2 was synthesized ﬁrst (Figures 2 and S2). The
synthesis started with the preparation of the chain 2a, in which
the C-terminal Arg36 was replaced by β-azido-alanine
carboxamide, and the chain 2b, in which N-terminal Arg37
was replaced by propargyl glycine. Both chains were “clicked”,
and the single-chain (Acm-protected) precursor 2c was puriﬁed
by RP-HPLC. Finally, the Cys-protecting acetamidomethyl
(Acm) groups were cleaved, and the analog 2 was allowed to
fold by air-induced oxidation.
Next, we synthesized the similar analog 3 from the chains 2a,
3a, and 3b (Figures 2 and S3). The only diﬀerence between
analogs 2 and 3 was that Met59 was substituted in 3 for
norleucine (Nle) to prevent the observed oxidation of Met59
Figure 1. The primary sequence and the 3D fold of human IGF-1. The
primary sequence of human IGF-1 (one-letter code, N-terminus is in
the left, C-terminus is in the right, upper panel); residues mutated in
this study (Arg36, Arg37 and Met59) are highlighted in yellow;
disulﬁde bridges: 47-52, 48-6, and 61-18. The organization of IGF-1
into B, C, A, and D domains is shown below the sequence by arrows,
and the 3D fold of its main chain is in the lower panel (1GZR.PDB).51
The gap in the protein chain (marked by a gray arrow) reﬂects a
typical lack of connectivity between Arg36-Ala38; Met59, mutated in
one of the analogs is shown in green, IGF-1 residues 39-66 are in light
blue, residues 3-35 are in pink; residues 67-70 and 1-2 were
disordered.
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side chain. Finally, we designed and made analog 4 (from the
chains 4a, 4b, and 4c, Figures 2 and S4), in which Arg36 was
preserved, the triazole link was formed between sites 37−38,
with an additional Arg at the position 39; these modiﬁcations
resulted in an analog that is two amino acids longer than native
IGF-1.
In general, the chains with propargyl glycine at the N-
terminus (2b, 3a, and 4b) gave better yields (15−18%) than
the azido chains 2a and 4a (6−13%). The preparation of the
precursor 2a was hampered by the formation of some
byproducts, which were identiﬁed as aspartimides (racemized)
at positions Asp20 and Arg21 (see analyses and model
experiments described in Supporting Information). This
problem was largely solved by the use of Fmoc-Asp(OEpe)
instead of Fmoc-Asp(OtBu), and the yield improved from 6%
to 10%, respectively. We also observed the generation of a
byproduct during the synthesis of the peptide 2b, due to the
oxidation of Met59 to methionine sulfoxide. This prompted
synthesis of analog 3, for which the chain 3a with Met59Nle
mutation was used.27 Although this resulted in a better purity of
the crude product 3a, the yields of HPLC puriﬁed peptides 2b
and 3a were similar (18% and 15%, respectively). Therefore,
the native Met59 was retained in peptide 4b, with only a
marginal oxidation of the ﬁnal product.
Our ﬁrst attempts (Figure S1) at the click ligation of the
azido and alkyne precursor chains were performed as described
previously,42,43 with cysteines protected as S-sulfonates.
However, we have not succeeded to isolate the desired
products here: None of the reaction conditions used (CuBr/
TBTA/DIPEA, CuBr/THPTA/DIPEA, CuI/DIPEA, CuSO4/
ascorbic acid/THPTA, or CuSO4/ascorbic acid in diﬀerent
organic or aqueous solvents with or without chaotropic agents)
was successful, that is, compatible with the use of S-sulfonates.
Therefore, the strategy for an eﬃcient disulﬁde pairing was
changed, and all subsequent precursor peptides were
synthesized with cysteines protected with Acm groups.
Diﬀerent conditions for the click reactions were investigated,
but the only eﬀective setup consisted of an excess of CuSO4/
ascorbic acid in tBuOH/water, and this methodology56,57 was
employed for the preparation of peptide chains 2c, 3b, and 4c.
The eﬀect of diﬀerent molar ratios of chain precursors for the
synthesis of 2c and 4c was also tested, and it was observed that
Figure 2. Primary structures of peptide precursors and analogs synthesized in this work. Amino acids are shown in one-letter code. The connecting
lines between Cys residues represent disulﬁde bridges. Unnatural structural features in peptides are highlighted in red or in blue. Red C in peptides
1a and 1b represents Cys residues protected by S-sulfonate groups. Blue C in peptides 2a, 2b, 2c, 3a, 3b, 4a, 4b, and 4c represents Cys residues
protected by Acm groups. Blue X in peptides 3a, 3b, and analog 3 is norleucine. Azido or propargyl amino acids in 2a, 2b, 3a, 4a, and 4b and
connecting triazole-containing moieties and 2c, 2, 3b, 3, 4c, and 4 are shown in blue as well. 1G and 37R in peptides 1a, 1b, and analog 1 are N-
terminal residues, and R36 and A70 in the same peptides are C-terminal residues. 1G is N-terminal glycine in peptides 2a, 2c, 3b, 4a, 4c, and analogs
2−4. 70A is C-terminal alanine in peptides 2b, 2c, 3b, 3c, and analogs 2 and 3. 72A is C-terminal alanine in peptides 4b, 4c, and analog 4. All
terminals of peptides and analogs are in the free forms.
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the cycloadditions at equimolar ratio of the precursor chains
gave lower yields than the reactions with 2-fold molar excess of
the azido chains. However, the optimum ratio of azido and
propargyl precursors for 3b was 1:1. Moreover, the use of more
than 0.5 μmol (about 2 mg) of the yield-limiting propargyl-
containing chain was ineﬀective. As a result, several click
reactions for each analog were preformed to accumulate a
suﬃcient amount of the material for their functional testing.
The yields of optimized click reactions were typically about
16%, 18%, and 7% for 2c, 3b, and 4c, respectively, after HPLC
puriﬁcation.
The ﬁnal part of the synthetic work was focused on the
optimization of an eﬃcient, and proper/native, formation of the
disulﬁde bonds in single-chain precursors 2c, 3b, and 4c.
Initially, an access of iodine in an acetic/hydrochloric acid
mixture was used to cleave the Acm groups from Cys side
chains in 2c (Figure S2).30 However, this was ineﬀective, as the
majority of the Acm groups remained uncleaved, even after 4 h.
Therefore, silver triﬂate was employed for the removal of the
Acm groups, without the puriﬁcation of an intermediate
product. Subsequently, the free −SH groups were “liberated”
from the Ag+ salt by the gaseous H2S, and the precipitated Ag2S
was removed by centrifugation. We followed here our
successful application of such an approach for the removal of
copper from synthesized compounds after click reactions.58−60
Finally, the dilution of the supernatant, and the removal of an
excess of the reductive H2S gas, was followed by a slow air
oxidation of the peptide, and its biomimetic folding, and the
products 2, 3, and 4 were isolated by RP-HPLC. The typical
yields of this last synthetic step were about 8% (0.5 mg) for 2,
5.7% (0.27 mg) for 3, and 1.7% (0.12 mg) for 4 (Figures S2−
S4), which provided suﬃcient material for their biological
characterization.
In summary, during the synthesis of peptide chain precursors
and analogs, we encountered problems with the aspartimide
formation in peptide 2a and partly also with the oxidation of
Met59 in peptide 2b. We also found that S-sulfonate protection
is not compatible with CuI-catalyzed click reaction and that
simultaneous cleavage of six Acm-protecting groups in
molecules of precursors with an access of I2 was ineﬀective
and had to be rectiﬁed by the use of silver triﬂate, followed by
the removal of Ag+ with a gaseous H2S.
Functional Characterization of the analogs. Binding
Aﬃnities to the Receptors. The analogs 2−4, and human
insulin and IGF-1 as controls, were tested for their binding to
human IGF-1R in membranes of mouse ﬁbroblasts and to
human IR-A in membranes of human IM-9 lymphocytes (Table
1, with the representative binding curves in Figures S5 and S6,
respectively).
The two-chain analog 1 has signiﬁcantly impaired binding for
IGF-1R of only about 3.5% of the native IGF-1. Similar low
binding (4.8%) was also detected for a single-chain analog 3, in
which Arg36 and Arg37 were replaced with β-azido-alanine and
propargylglycine, respectively, connected by a triazole link, and
with Met59Nle mutation. Interestingly, analog 2, a “wild-type”
homologue of 3 with preserved native Met59, showed markedly
stronger 20.8% aﬃnity than analog 3.
The insertion of Arg36 and Arg39 in analog 4, adjacent to
the connecting triazole-containing 37−38 moiety, further
enhanced IGF-1R binding aﬃnity of this analog to almost
25% of the native IGF-1 binding.
Native human IGF-1 has only 1.0% binding aﬃnity for IR-A
compared to human insulin, but all analogs were even
signiﬁcantly weaker than human IGF-1 in binding to this
receptor (Table 1).
Autophosphorylation of Receptors and Akt Activation.
We also investigated the ability of analogs 1−4 to induce the
autophosphorylation of IGF-1R (Figure 3A,C), and subsequent
downstream phosphorylation of the Akt protein (pAkt) (Figure
3B,D), in response to their binding to this receptor. The
potencies of the analogs were measured in IGF-1R-transfected
3T3 ﬁbroblasts with high receptor population (Figure 3A,B)
and, in parallel, in the non-transfected ﬁbroblasts with a natural,
that is, much lower, mouse IGF-1R population (Figure 3C,D).
We also determined the ability of analogs 1−4 to stimulate the
autophosphorylation of IR-A receptor in the IR-A-transfected
ﬁbroblasts (Figure 3E). The cells were stimulated for 10 min at
10−8 M concentration, and signals compared for all analogs
(Figure 3A−E). Subsequently, the dose−response curves were
measured for each analog (Figure 3F).
Table 1. The Receptor-Binding Aﬃnities of Analogs 1−4 Reported in This Worka
Analog
Kd ± SD [nM] (n) for human IGF-1R
in mouse ﬁbroblasts
Relative binding aﬃnity for
human IGF-1R [%]
Kd ± SD [nM] (n) for human IR-A in
IM-9 lymphocytes
Relative binding aﬃnity for
human IR-A [%]
Human IGF-1 0.24 ± 0.10 (5)b 100 ± 42 23.8 ± 11.5 (3)c,d 1.0 ± 0.5
0.24 ± 0.12 (5) 100 ± 50
0.12 ± 0.01 (5) 100 ± 8.3
Human insulin 291.8 ± 54.3 (3)b,e 0.08 ± 0.01 0.24 ± 0.05 (5)c 100 ± 21
0.20 ± 0.04 (5) 100 ± 20
0.12 ± 0.04 (3) 100 ± 33
0.32 ± 0.09 (4) 100 ± 28
1 6.74 ± 2.62 (3)e 3.56 ± 1.38** 48.2 ± 5.0 (3)f 0.41 ± 0.04*
2 1.15 ± 0.45 (4)g 20.8 ± 8.1** 48.3 ± 7.5 (3)h 0.25 ± 0.04*
3 5.04 ± 2.31 (3)d 4.76 ± 2.18** 113 ± 53 (3)d 0.21 ± 0.09*
4 0.49 ± 0.12 (3)i 24.5 ± 6.0*** 75.1 ± 6.2 (3)j 0.43 ± 0.04*
aThe values of Kd and relative binding aﬃnities (relative receptor-binding aﬃnity is deﬁned as (Kd of human insulin or IGF-1/Kd of analog) × 100)
of human IGF-1, insulin, and the analogs were determined for human IGF-1R in membranes of mouse ﬁbroblasts and human IR-A in membranes of
human IM-9 lymphocytes. Asterisks indicate that binding of the ligand diﬀers signiﬁcantly from that of IGF-1 (*p < 0.05; **p < 0.01; ***p < 0.001).
bFrom Vikova et al. (ref 57). cFrom Krizkova et al. (ref 55). dRelative to human insulin Kd value of 0.24 ± 0.05 (n = 5).
eRelative to human IGF-1 Kd
value of 0.24 ± 0.10 (n = 5). fRelative to human insulin Kd value of 0.20 ± 0.04 (n = 5).
gRelative to human IGF-1 Kd value of 0.24 ± 0.12 (n = 5).
hRelative to human insulin Kd value of 0.12 ± 0.04 (n = 3).
iRelative to human IGF-1 Kd value of 0.12 ± 0.01 (n = 5).
jRelative to human insulin Kd
value of 0.32 ± 0.09 (n = 4).
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In general, the abilities of the analogs to stimulate
autophosphorylation of IGF-1R and phosphorylation of
intracellular Akt protein paralleled their IGF1-R binding
aﬃnities. The lowest IGF-1R autophosphorylation was
observed for the two-chain analog 1 (4% binding) and for
analog 3 with Met59Nle substitution (5% binding). However,
interestingly, the analog 2 that lacks Arg36 and Arg37 activates
IGF-1R somehow more strongly than analog 4, which has
Arg36 and Arg39 (Figure 3A), despite their reversed binding
aﬃnities of 21% and 24%, respectively. The ability of these
analogs to activate/phosphorylate Akt protein follows this
trend, although the diﬀerences between 2 and 4 are less
signiﬁcant here and similar to the native IGF-1 (Figure 3B). We
compared the data measured for analogs 2 and 4, using the
two-tailed t test to determine the statistical signiﬁcance of the
observed diﬀerences, and only the stimulation of autophos-
phorylation of IGF-1R in transfected ﬁbroblasts appeared
statistically signiﬁcant (p = 0.02), while the diﬀerence in
binding activities was negligible (p = 0.82). In general, it
appears that the transfected cells (Figure 3A,B) respond more
Figure 3. Receptor autophosphorylation and pAkt activation induced by analogs 1−4, human IGF-1, and human insulin (HI). In (A−E), the cells
were stimulated for 10 min with proteins at 10−8 M concentration only. In (F), the dose responses for proteins at several diﬀerent concentrations
were determined. In all panels, the same color scheme was used: human IGF-1 in black, analog 1 in red, analog 2 in green, analog 3 in blue, analog 4
in orange, and human insulin (HI) in yellow. (A) IGF-1R autophosphorylation in IGF-1R-transfected 3T3 ﬁbroblasts. (B) pAkt activation in IGF-
1R-transfected 3T3 ﬁbroblasts. (C) IGF-1R autophosphorylation in non-transfected 3T3 ﬁbroblasts. (D) pAkt activation in non-transfected 3T3
ﬁbroblasts. (E) IR-A autophosphorylation in IR-A-transfected 3T3 ﬁbroblasts. In most cases, the scatter plots show means ± SD of several
independent measurements. However, in some cases where a low amount of material was available (for analog 4 in C−D), the plots show mean ±
range calculated from two measurements. HI is human insulin. (F) Concentration-dependent eﬀects of analogs on IGF-1R autophosphorylation in
IGF-1R-transfected 3T3 ﬁbroblasts. Asterisks indicate that phosphorylation of the receptor or Akt induced by the ligand diﬀers signiﬁcantly from that
of IGF-1 (*p < 0.05; **p < 0.01; ***p < 0.001).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01331
J. Med. Chem. 2017, 60, 10105−10117
10109
sensitively to the stimulation with analogs than the non-
transfected cells (Figure 3C,D), and this trend is visible
especially in Akt activation (Figure 3B,D). It seems that higher
sensitivity of the transfected cells alleviates the diﬀerences in
binding aﬃnities of analogs.
All analogs are also less potent than native IGF-1 in the
stimulation of IR-A autophosphorylation in IR-A-transfected
cells (Figure 3E).
Finally, the dose−response curves of IGF-1R autophosphor-
ylation ability of analogs 1−4 and IGF-1 (Figure 3F) indicate
that all analogs are weaker than IGF-1, where analog 2 is the
strongest and analog 1 is the weakest, without a major
diﬀerence between 3 and 4; all in general agreement with the
previous results.
■ DISCUSSION
Chemistry. The low yield (0.6%) of the recombination
reaction, that is, a biomimetic formation of disulﬁdes, for analog
1 is similar to the rather poor yields of some insulin analogs
prepared previously and is signiﬁcantly lower than typical yields
for native human insulin (∼10%).43 The poor folding ability of
two separate chains of IGF-1 is also reﬂected in the complexity
of the byproducts in the reaction mixture, where we identiﬁed,
for example, a misfolded, inactive, but correct molecular mass,
analog; the active analog 1 was found there as a rather minor
peak (Figure S9). Misfolded and inactive IGF-1 molecules,
speciﬁcally with “swapped” pairs of disulﬁdes, that is, Cys6-
Cys47 and Cys48-Cys52, instead of the correct Cys6-Cys48
and Cys47-Cys52, were identiﬁed previously in preparations of
synthetic IGF-1 and its analogs.20 However, the particularly
poor yield of 1 clearly indicates the importance of a single-chain
form of IGF-1 for its eﬀective folding. Nevertheless, the
amounts of analog 1 were suﬃcient for its biological
characterization, especially with the recycling of chains 1a and
1b and repetition of the reaction.
We assumed that the single-chain IGF-1 analogs, with six free
-SH groups, will oxidize themselves to a native conformation
and that better folding properties of the single, rather than two-
chain, IGF-1 analogs can be expected. However, as mentioned
above, the 70-amino acid chain of IGF-1 is too long for an
eﬃcient solid-phase peptide synthesis. Therefore, we inves-
tigated here the possibility of connecting two IGF-1 fragments
by CuI-catalyzed 1,3-dipolar cycloaddition of azides and
alkynes, which would generate 1,2,3-triazole in the main-chain
of IGF-1 analog. A similar approach was used by Valverde et
al.27 to connect three fragments of cysteine-protease protein
inhibitor cystatin (98 amino acids). However, this did not
require the formation of native disulﬁde bonds in this protein.
As 1,4-disubstituted 1,2,3-triazoles are considered to be good
mimics of the peptide bond,28 it might be possible that their
incorporation into the peptide chain in the IGF-1 C domain
could be tolerated by IGF-1R. We were also encouraged here
by our similar approach in the cross-linking of insulin B-chain
with 1,2,3-triazole bridges, in which some highly potent IR
analogs were obtained.57
Our ﬁrst attempts at the clicking of two IGF-1 fragments
involved the use of IGF-1 fragment 1−36 with β-azido alanine
at position 36 and the IGF-1 fragment 37−70 with the
propargyl glycine at position 37; all cysteines in these peptides
were protected as S-sulfonates, which assured their good
solubility and better separation on the HPLC. However, all our
experiments (not shown) for connecting these fragments by
CuI-catalyzed click reaction were unsuccessful (Figure S1). We
concluded that the S-sulfonate groups are incompatible with
the reaction, probably due to the S-sulfonate-copper chelation,
which could lead to an undesired Cu-mediated folding of IGF-1
chains and steric blocking of the azido and alkyne groups,
making them inaccessible for cycloaddition.
For this reason, we changed the Cys-protection strategy,
synthesizing peptide chains with acetamidomethyl-protected
cysteines, assuming that the Acm protection should not
interfere with the clicking step, oﬀering also several diﬀerent
alternative deprotections.61 Unfortunately, the ﬁrst synthesis of
2a was hampered by a considerable amount of other, hardly
separable, byproducts, identiﬁed as racemized aspartimides at
positions Asp20-Arg21 (i.e., peptide 2ax, see Figures S2, S12,
and S28). The appearance of Asp-Arg aspartimides is rather
rare, but not unusual in peptide chemistry,62 as the Arg(Pbf)/
Cys(Acm) protection strategy may promote this side reaction
to a greater extent.63 To test such a scenario in our chemical
environment, we performed a model experiment (Supporting
Information, pp 27−28) in which, with a model peptide 7, Phe-
Val-Cys(Acm)-Gly-Asp(OtBu)-Arg(Pbf), we were able to
generate and characterize (Figures S29, S30 and Scheme S1,
Tables S1−S3) racemized aspartimides that were similar to the
ones found in 2ax. Therefore, we used a Fmoc-Asp(OEpe)
derivative,64 which helped to eliminate this problem in 2a and
4a. Hence, it seems that the formation of Asp20-Arg21
aspartimide in 2ax was both sequence and side-chain
protection-type dependent, as such byproducts were not
observed in 1a, 2b, 3a, and 4b.
As mentioned above, the eﬀective reactions and isolation of
the products in the cycloaddition step required a reaction setup
with a high excess of CuSO4/ascorbate in water-tBuO,
56,57 but
the addition of some click accelerators65,66 or reactions in
organic solvents25 did not lead to the desired products. It is
possible that the participation of bulky copper chelating agents
like TBTA or THPTA is not favorable for steric reasons, if large
peptide precursors are used. The failure of CuBr or CuI/
DIPEA strategy in DMF could be due to a need for an eﬀective
protein hydration that is better in water-tBuOH. Although all
reactions performed here were ineﬀective if they were scaled up
above ∼2−4 mg per chain, some amount of the precursors
could be recycled, and the reactions repeated. Both single-chain
peptides without arginines in the proximity of the azido and
alkyne precursor residues (2c and 3b) gave better yields than
peptide 4c with the triazole-neighboring arginines. This could
be due some steric shielding of the azido and alkyne moieties
by the bulky arginine side chains.
Overall, we were able to prepare full-length IGF-1 chains on
a preparative scale, still within reasonable yield ranges (7−
18%). Our results underline the diﬃculty of click reactions
where both precursors are large peptides, or proteins, compared
to click reactions with small peptides/molecules, which usually
proceed quickly and quantitatively.25,26
The ﬁnal synthetic steps, that is, the deprotection of cysteines
and the formation of physiological S−S bridges, were crucial for
the success of the synthesis. Interestingly, the use of iodine in
acetic acid/HCl61 was not successful here, due to an incomplete
cleavage of the Acm groups. One of the reasons for this could
be the presence of six Acm groups accumulated in each
molecule of the precursor, while only two Acm groups are
usually simultaneously deprotected by I2 for a directed
formation of the disulﬁde.30 For this reason, we used silver
triﬂate, instead of I2, for the cleavage of the Acm groups,
without the puriﬁcation of an intermediate product. Interest-
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ingly, this three-step procedure was relatively eﬀective and
successful, providing 6−8% yields for analogs 2 and 3, which
are comparable to our yields of syntheses of human insulin
from its separate A and B chains (∼10%). However, calculated
for a single folding step,43 they were also much better than the
∼0.6% yields for the two-chain IGF-1 analog 1. The less
eﬀective (1.7%) folding of analog 4 may result from the
presence of Arg36 and Arg39 in this analog and, consequently,
from a longer C domain than in 2 and 3. It seems that the
insertion of two additional Arg residues, rather than the
presence of the triazole-containing connecting moiety, lowered
the folding eﬃciency of this IGF-1 precursor. The folding of 2−
4 was accompanied by the appearance of inactive misfolded
“swapped” products (Figure S16), but to a lesser extent than in
the case of 1 (Figure S9), certainly due to the single-chain
character of precursors for 2−4.
The clicked polypeptides reported here are, to our
knowledge, unique examples of the use of triazole-forming
chemistry for the preparative production of large peptides/
small proteins (relative molecular weights about 8000 Da), with
a native pattern of disulﬁde bridges. The middle position of the
connecting triazole bridge in the protein main chain further
validates the results. Moreover, the only few examples of true
proteins with main-chain triazoles that were reported27,67 did
not contain disulﬁde bridges, which present additional
challenges to such an approach.
Biology. Analog 1 retained some IGF-1R binding aﬃnity,
but its binding potency was severely impaired (3.5%) in
comparison with the potency of the native IGF-1 (Table 1).
This strongly suggests that the cleavage of Arg36-Arg37 peptide
bond, if it occurs in vivo, is not a part of IGF-1 processing, but
is rather a degradation-like step of this hormone, which leads to
a much less active protein. Whether such cleavage represents
some physiological attenuation of IGF-1 activity cannot be
excluded, but it requires further, complex studies on this
hormone, especially on in vivo-derived material.
The incorporation of the triazole bridge formed from β-
azido-alanine at 36 and propargylglycine at 37 reduced the
binding aﬃnity of the analog 2 to about 21% of the binding
aﬃnity of the native IGF-1. However, this aﬃnity drop is less
signiﬁcant than the eﬀect of Ala36-Ala37 mutation of this
hormone, which reduced its receptor binding to about 5%.47
Therefore, it seems that the loss of Arg36-Arg37 in 2 is,
somehow, compensated for by the triazole ring and/or the
neighboring ethyl carboxymido (at 36) and ethyl amino (at 37)
moieties. Some insight into the functional diﬀerences of the
analogs 1−4 may be facilitated by a direct comparison of their
connecting motifs shown in Figure 4. In 2, this motif is three
atoms longer than the peptide bond of the native IGF-1, and
the only diﬀerence between analog 2 and 3 is Met59Nle
mutation in analog 3. This exchange reduced the IGF-1R
aﬃnity of the analog 3 to 5%, in agreement with the work of
Shooter et al.,68 where Met59Phe mutation resulted in the 17-
fold decrease in IGF-1R binding. Therefore, analog 3 further
highlights the importance of the sulfur atom in Met59 for
receptor binding, which is not compensated for in 3 by the Nle
alkyl chain. The highest IGF-1R binding aﬃnity in the series
from Table 1 was found for analog 4 (almost 25% of native
IGF-1). However, statistical analysis (see above) showed that
the diﬀerence in binding aﬃnities of 4 and 2 is not signiﬁcant,
hence, both analogs are rather similar in this aspect. Although
analog 4 retains arginines in the C-loop, they are at sites 36 and
39, not at their native positions 36−37 (Figures 2 and 4).
Therefore, the Cα atoms of the arginines in 4 are separated by
eight extra backbone atoms plus triazole ring and carboxamide
and amino moiety. Interestingly, this extension did not reduce
the binding aﬃnity of this analog in comparison with analog 2,
indicating a relative tolerance of IGF-1R for the modiﬁcations
in this part of the C domain. However, it is also possible that at
least one of the Arg36/Arg39 in 4 (e.g., Arg36) occupies a
similar position on the receptor as one of the natives Arg36−
37. This result opens up new possibilities for the use of
diﬀerent side chains, and motifs, at positions adjacent to the
triazole ring, that is, 36 and 37 in 2 and 37 and 38 in 4.
However, such approaches depend on the development of
available functionalized azides and alkynes suitable for the solid-
phase peptide synthesis.
All analogs 1−4 have reduced binding aﬃnities for the
isoform A of the insulin receptor (Table 1) compared to native
IGF-1. However, it seems that this decrease (21−43% of native
IGF-1) is lower than for the IGF-1R (3−25% of native IGF-1),
indicating that the C domain of IGF-1 is less important for IR-
A binding than for an eﬀective hormone complex formation
with the IGF-1R.
The abilities of analogs 1−4 to induce the autophosphor-
ylation of IGF-1R and IR-A and to activate the downstream Akt
generally reﬂected their binding aﬃnities for these receptors.
This trend is especially visible in non-transfected ﬁbroblasts,
with a natural population of IGF-1R (Figure 3C,D). It seems
that the high non-natural concentration of IGF-1R in IGF-1R-
transfected ﬁbroblasts is behind their higher sensitivity to the
stimulation by the analogs, rather than diﬀerences in binding
aﬃnities of human IGF-1 for rat and human IGF-1R; this levels
up the diﬀerences in binding aﬃnities of analogs. The reason
for this phenomenon could be in the “disproportional”
populations/distributions of receptors and intracellular signal-
ing proteins. In this respect, the native ﬁbroblasts, with
naturally lower population of IGF-1R, seem to be a better
model. The only apparent exception here could be observed in
a higher receptor stimulating activity of analog 2 than of analog
4 despite slightly reverse binding aﬃnities. This “discrepancy” is
interesting, but should be treated with caution, due to the low
statistical signiﬁcance of the diﬀerences between biological
properties of analogs 2 and 4 mentioned above. Nevertheless,
Figure 4. Comparison of the connecting motifs at positions 36−37 or
37−38 in analogs 2−4 with the native human IGF-1. Cα atoms are
marked by residue numbers.
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we observed a similar phenomenon in the case of insulin-IGF
hybrids, that is, human insulin molecules with the B chain
prolonged for C domain amino acids of human IGF-2.55
However, it is rather diﬃcult to explain such a discrepancy
without a structure of the analogs in a complex with the
receptor, and even crystal/NMR structures of the analogs
would provide only very limited clues. It is possible that only a
complex with the so-called site 2 of IGF-1 receptor would shed
light on the slightly diﬀerential activation/binding observed
here, and only the structures of insulin and IGF-1 complexed
with site 1 of the IR are currently available.69,70 Nevertheless, as
it was observed that diﬀerential binding kinetics of insulin-like
analogs, that is, slower or faster kon or koff rates, can inﬂuence
their metabolic or mitogenic biological responses,71 this could
be the case of the apparent diﬀerences between analogs 2 and
4.
Finally, analogs 1−4 do not appear to possess the properties
of IGF-1R antagonists or partial antagonists, as was observed
for the IGF-1 Glu36-Glu37 mutant.49,50 It is possible then that
the antagonism observed for the Glu36-Glu37 IGF-1 analog
results from a reversed, negatively charged glutamic acid’s side
chains, instead of the arginine basic guanidine groups, and that
the replacement of the Arg36-Arg37 pair, by moieties shown in
Figure 4, is not suﬃcient to elicit a similar antagonistic eﬀect.
■ CONCLUSIONS
In summary, we developed a new method for the total chemical
synthesis of human IGF-1 analogs, which entails a solid-phase
synthesis of two IGF-1 precursor chains, and their ligation by
CuI-catalyzed azide−alkyne cycloaddition chemistry. This
relatively straightforward methodology presents a viable
synthetic alternative to the previously established IGF synthetic
strategies, which employed native ligation. The connection of
two IGF-1 precursor chains by triazole-containing moieties was
relatively well tolerated by IGF-1R and IR-A, both in terms of
receptor binding and activation, and can thus represent a
convenient and relatively straightforward synthetic strategy for
the design of new analogs of this important human hormone
with non-standard protein modiﬁcations. We also found that
the disruption of the connectivity of the IGF-1 Arg36-Arg37
peptide bond deactivates this protein, hence it is unlikely that
such cleavage represents a maturation step of this hormone in
vivo.
■ EXPERIMENTAL SECTION
Unless otherwise stated, reagents and materials were obtained from
commercial suppliers (Sigma-Aldrich-Fluka, Merck) and used without
puriﬁcation.
Solid-Phase Peptide Synthesis. Peptide chains were prepared by
manual solid-phase synthesis in plastic syringes, equipped either with a
Teﬂon frit or with ABI433A peptide synthesizer. Standard Fmoc
amino acids (Iris Biotech, Gmbh, Germany) were used, and couplings
were done with HBTU/DIPEA or DIC/HOBT reagents in DMF.
Usually two couplings (60 min) with Fmoc-amino acids (3−5 equiv
for manual synthesis and 10 equiv for automated synthesis) were done.
In manual synthesis, the eﬃciency of the couplings was monitored by
the Kaiser test, and the amount of cleaved Fmoc group (20%
piperidine in DMF for 5 and 20 min) was determined spectrophoto-
metrically (extinction coeﬃcient 7040 M−1 cm−1 at 301 nm). Fmoc-
Asp(OEpe)-OH was prepared as described in the Supporting
Information and used for the syntheses of 2a and 4a. Fmoc-β-azido-
(S)-Ala-OH was prepared as described by Pıćha et al.72
The peptide chains with the C-terminal β-azido-(S)-Ala carbox-
amide, 2a and 4a, were synthesized on Rink amide AM LL resin or
Nova PEG Rink amide (Merck-Novabiochem), respectively. Fmoc-
(S)-propargylglycine-OH was purchased from Sigma-Aldrich-Fluka.
The peptide chains 1a, 1b, 2b, 3a, and 4b with a free carboxy terminus
were synthesized on Wang-ChemMatrix LL resins, preloaded with
Fmoc-Ala or Fmoc-Arg(Pbf) (PCAS BioMatrix Inc.). The peptides
were cleaved with 91.5% TFA, 2.3% H2O, 2.3% thioanisol, 2.3%
phenol, 1.15% DODT, and 0.45% TIS for 2−4 h. Subsequently, the
crude peptides were precipitated from the cold diethyl ether (in at
least 10-fold excess), centrifuged, and dried. The precipitates of crude
peptides 1a and 1b were immediately converted to S-sulfonates and
subsequently desalted, as previously described in detail.42,43 Finally, all
peptide chains were puriﬁed by RP-HPLC.
Peptide and Compound Characterization. The precursor
peptides (1a, 1b, 2a, 2b, 2c, 3a, 3b, 4a, 4b, and 4c), and the resulting
IGF-1 analogs 1−4 were puriﬁed and the purity of compounds
analyzed by RP-HPLC. HRMS spectra of all compounds, peptides, and
analogs were obtained on a FTMS mass spectrometer LTQ-orbitrap
XL (Thermo Fisher, Bremen, Germany) in electrospray ionization
mode. The purity of target compounds 1−4 was ≥95% (RP-HPLC,
HR-MS). The identity and purity of analogs 1−4 were furthermore
veriﬁed by N-terminal sequencing. Analytical data for all peptide
precursors, IGF-1 analogs 1−4, and conditions for NMR measure-
ments of 2a and model compounds 7 are provided in the Figures S7−
S30, Tables S1−S3, and Scheme S1. Melting points of compounds 5
and 6 were determined on a Boetius block and are uncorrected. 1H
and 13NMR spectra of compounds 5 and 6 were measured on a Bruker
AVANCE-600 spectrometer (1H at 600.13 MHz, 13C at 150.9 MHz)
in CDCl3, DMSO-d6, CD3OD, or D2O solution at 300 K. The 2D-
H,H-COSY, 2D-H,C-HSQC and 2D-H,C-HMBC spectra were
recorded and used for the structural assignment of proton and carbon
signals. IR spectra of compounds 5 and 6 were recorded on Bruker IFS
55 Equinox apparatus.
Peptide 1a. The yield (RP-HPLC) was 4.3% (27 mg). HRMS-ESI:
Monoisotopic Mr calcd for C169H253N45O60S4 4000.701, found
4000.677.
Peptide 1b. The yield (RP-HPLC) was 12.2% (51 mg). HRMS-
ESI: Monoisotopic Mr calcd for C162H267N49O60S9 4146.683, found
4146.665.
Analog 1. Recombination of chains 1a (17 mg, 4.27 μmol) and 1b
(33 mg, 7.95 μmol) was done according to the procedure previously
described in detail.42,43 The typical yield of the analog 1 (relative to
chain 1a as the limiting component of the reaction) after RP-HPLC
puriﬁcation was about 0.6% (0.2 mg). HRMS-ESI: Monoisotopic Mr
calcd for C331H514N94O102S7 7661.597, found 7661.617.
Peptide 2a. When Fmoc-Asp(OtBu)-OH was used, the yield (RP-
HPLC) was 6.2% (22 mg). HRMS-ESI: M r calcd for
C172H256N48O55S2 3937.815, found 3937.818. The aspartimide
derivative of 2a (with an aspartimide bond at Asp20-Arg21, that is,
peptide 2ax, see in the Supporting Information) was puriﬁed (Figure
Scheme 1a
aReagents, conditions, and yields (a) DIC, DMAP, 3-ethyl-3-pentanol, DCM 0 °C 1 h, then rt 48 h (91%); (b) 10% Pd/C, H2, 10 psi, methanol 12
h; (c) Fmoc-OSu, NaHCO3, water and dioxane, 0 °C 1 h, then rt overnight (65% over two steps).
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S28) as well, and the yield was 8.6% (30 mg). HRMS-ESI Mr calcd for
C172H254N48O54S2 3919.805, found 3919.809.
If Fmoc-Asp(OEpe)-OH (6) was used for the synthesis, the yield
(RP-HPLC) was 10.1% (120 mg). HRMS-ESI: Mr calcd for
C172H256N48O55S2 3937.815, found 3937.819. Undesired aspartimide
byproduct was not found in this case.
Peptide 2b. The yield (RP-HPLC) was 18.5% (75 mg). HRMS-ESI
Mr calcd for C173H280N50O52S5 4049.941, found 4049.945.
Peptide 2c. In general, the click reactions were performed according
to the protocol previously published by Vikova et al.,57 but with a few
modiﬁcations. Brieﬂy, the typical reaction mixture contained the linear
peptide 2a (4 mg, 1.02 μmol) and 2b (2 mg, 0.49 μmol), which were
dissolved in 4.5 mL of a tert-butanol:water mixture (2:1, v/v). Next,
the ascorbic acid (5.5 μmol) and CuSO4·5 H2O (4.80 μmol) were
added in a minimum volume of water (the mixture was freshly
prepared). The reaction mixture proceeded with stirring at 40 °C
overnight. The precipitated product was removed from the reaction
mixture by centrifugation and was puriﬁed using RP-HPLC (C4
column). The typical yield (RP-HPLC, relative to the chain 2b as the
limiting component of the reaction) was about 16% (0.6 mg). HRMS-
ESI Mr calcd for C345H536N98O107S7 7987.756, found 7987.768.
Analog 2. Clicked peptide 2c (6.6 mg, 0.83 μmol) was dissolved in
1 mL of TFA with 250 mM silver triﬂate and 25 mM anisole and
allowed to react for 1 h in an ice bath. The deprotected peptide was
removed from the solution by precipitation with cold diethyl ether.
The crude peptide was dissolved (60 μM) in degassed 0.1 M Gly/
NaOH buﬀer (pH 10.5), and then the reaction mixture was treated
with gaseous H2S
58−60 to remove Ag+ ions from cysteine salts. The
precipitated Ag2S was removed by centrifugation. The supernatant,
containing the peptide with free SH groups, was diluted to 30 μM
concentration (by the same buﬀer) and purged with argon to remove
the excess hydrogen sulﬁde. The reaction mixture was brieﬂy purged
with air and allowed to oxidize in an opened ﬂask without stirring for 3
days at 4 °C. The crude target compound 2 was desalted on a C4-
cartridge (Macherey-Nagel) and puriﬁed using RP-HPLC (C4
column). The yield (RP-HPLC) was 8% (0.5 mg). HRMS-ESI Mr
calcd for C327H500N92O101S7, 7555.486, found 7555.502.
Peptide 3a. The yield (RP-HPLC) was 15% (46 mg). HRMS-ESI
Mr calcd for C174H282N50O52S4 4031.984, found 4031.988.
Peptide 3b. The compound was prepared from 3a (2 mg, 0.5 μmol)
and 2a (2 mg, 0.51 μmol) according to the procedure described for 2c.
The typical yield (RP-HPLC) was about 18.5% (0.74 mg). HRMS-ESI
Mr calcd for C346H538N98O107S6 7969.799, found 7969.801.
Analog 3. Analog 3 was prepared from 3b (5 mg, 0.63 μmol) by the
method described for 2. The yield (RP-HPLC) was 5.7% (0.27 mg).
HRMS-ESI Mr calcd for C328H502N92O101S6 7537.530, found 7537.551.
Peptide 4a. The yield (RP-HPLC) was 13.8% (170 mg). HRMS-
ESI Mr calcd for C178H268N52O56S2 for 4093.916, found 4093.923.
Peptide 4b. The yield (RP-HPLC) was 16.6% (140 mg; 33 μmol).
HRMS-ESI Mr calcd for C179H292N54O53S5 4206.042, found 4206.047.
Peptide 4c. Peptide 4c was prepared from peptides 4a (4 mg, 0.98
μmol) and 4b (2 mg, 0.48 μmol) by the method described for 2c. The
typical yield (RP-HPLC, relative to the chain 4b as the limiting
component of the reaction) was 7.3% (0.29 mg). MS-ESI Mr calcd for
C357H560N106O109S7 8299.958, found 8299.987.
Analog 4. Analog 4 was prepared from 4c (7.5 mg, 0.9 μmol) by
the method described for analog 2. The yield (RP-HPLC) was 1.7%
(0.12 mg). HRMS-ESI Mr calcd for C339H524N100O103S7 7867.688,
found 7867.709.
(2S)-N-Benzyloxycarbonylaspartic Acid 1-Benzyl-4-((3-ethyl)-
pent-3-yl)ester 5. Intermediate 5 was prepared using a slightly
modiﬁed method described previously in a patent.64 Brieﬂy, DIC (870
μL; 5.63 mmol) was added under stirring and ice-cooling to a solution
of Cbz-Asp-OBn (5 g; 14 mmol) and DMAP (0.34 g; 2.8 mmol), and
3-ethyl-3-pentanol (4.8 g; 42 mmol) in 25 mL DCM was added DIC.
The cooling was ﬁnished, and the mixture was allowed to react at rt 16
h. Addition of DIC (870 μL) was repeated twice, and the total reaction
time was 48 h. The excess of DIC was eliminated by quenching with
glacial acetic acid, and the volatile material was evaporated in vacuo to
give a yellow residue, which was puriﬁed by ﬂash chromatography on
silica gel using a linear gradient of ethyl acetate in petroleum ether.
Yield 5.8 g (91%). Colorless oil. Rf = 0.74 (20% ethyl acetate/toluen).
[α]D
20 = +14° (c = 0.669 ; CHCl3).
1H NMR (500 MHz, CDCl3): 0.70
(9H, t, J = 7.5, 3× CH3), 1.71 (6H, q, J = 7.5, 3× CH2), 2.96 (1H, dd, J
= 17.2 and 4.5, CO-CHaHb-), 2.77 (1H, dd, J = 17.2 and 4.5, CO-
CHaHb-), 4.56 (1H, dt, J = 8.8, 4.5 and 4.5, > CH-N), 5.05 (1H, d, J =
12.2, O-CHaHb-), 5.08 (1H, d, J = 12.2, O-CHaHb-), 5.10 (1H, d, J =
12.4, O-CHaHb-), 5.14 (1H, d, J = 12.4, O-CHaHb-), 5.77 (1H, d, J =
8.7, -NH-CO), 7.25−7.30 (10H, m, 2× C6H5);
13C NMR (125.7
MHz, CDCl3): 7.53 (3× CH3); 26.63 (3× CH2); 37.27 (CH2); 50.53
(CH-N); 66.95 and 67.40 (2× CH2-O), 90.06 (C-O), 127.95(2),
128.08, 128.17(2), 128.32, 128.45(2) and 128.49(2) (10× ArCH-),
135.18 and 136.18 (2× Ar > C), 155.98 (N-CO), 169.61 and
170.75 (2× O-CO). IR (CCl4) νmax cm
−1 3433 m, 3353 m (NH);
2972 s, 2883 m, 1380 s (CH3); 2943 s (CH2); 1751 vs + br (CO)
esters; 1727 vs (CO) carbamate; 3091 w, 3066 w, 3034 w, 1500 s,
1456 s, 1175 s, 1028 s, 1003 s, 737 s, 697 m (ring). HRMS (ESI) calcd
for C26H33O6NNa [M + Na]
+ 478.220, found: 478.220.
The synthesis of Fmoc-Asp(OEpe)-OH 6 is summarized in Scheme
1.
(2S)-N-((9H-Fluoren-9-ylmethoxy)carbonyl))aspartic acid 4-((3-
ethyl)pent-3-yl)ester 6. Intermediate 5 (6.9 g; 15.1 mmol) was
charged to a nitrogen ﬂushed glass pressure bottle, dissolved in 80 mL
of methanol, and then 500 mg of 10% Pd/C was added. The mixture
was vigorously stirred and allowed to react under the atmosphere of
hydrogen (15 psi) at RT for 12 h. TLC analysis (50% ethyl acetate/
toluen) revealed that the starting compound had completely
disappeared. The catalyst was ﬁltered oﬀ through Celite, and the
ﬁlter cake was washed with 100 mL of methanol. The ﬁltrate was
evaporated in vacuo to give 3.5 g of light brown residue, which was
immediately dissolved in 50 mL of aqueous solution of NaHCO3 (2.5
g; 30.2 mmol). The ﬂask was placed in an ice bath, and Fmoc-OSu
(5.1 g; 15.1 mmol) in 50 mL of dioxane was added dropwise under
stirring. After the addition of the total amount of Fmoc-OSu, stirring
continued for 1 h at 0 °C and then overnight at room temperature.
Thereafter, 10% aqueous solution of citric acid was added to the
reaction mixture until pH ∼3−4 was reached, followed by 200 mL
water. The solution was transferred to a separator funnel and extracted
with 4 × 100 mL of ethyl acetate. Combined organic layers were
washed consecutively with 2 × 50 mL water, 2 × 50 mL brine, and
dried over anhydrous Na2SO4. The ﬁltrate was evaporated to aﬀord a
dark yellow oil, which was puriﬁed by ﬂash chromatography on silica
gel, using a linear gradient of ethyl acetate in toluene. Yield 4.5 g (65%
over two steps). Bright yellow semisolid. Rf = 0.67 (ethyl acetate-
acetone-ethanol-water 6/1/1/0.5). [α]D
20 = −8.6° (c = 0.326 ; DMF).
1H NMR (600 MHz, DMSO): 0.73 (9H, t, J = 7.5, 3× CH3), 1.72
(6H, q, J = 7.5, 3× CH2), 2.53 (1H, dd, J = 15.9 and 9.1, CO-CHaHb-
), 2.78 (1H, dd, J = 15.9 and 4.6, CO-CHaHb-), 4.20 (t, J = 6.5, > CH-
), 4.25 (3H, m, > CH-N and −CH2-O), 7.38 (1H, br, -NH-CO), 7.31
(2H, m), 7.41 (2H, m), 7.69 (2H, m) and 7.88 (2H, m) (2×
C6H4);
13C NMR (150.9 MHz, DMSO): 7.60 (3× CH3); 26.50 (3×
CH2); 37.27 (CH2); 46.83 (>CH-); 66.81 (CH2 -O), 87.83 (C-O),
120.31(2), 125.44(2), 127.26(2) and 124.83(2) (8× Ar CH-),
140.91(2), 144.02 and 144.02 (4× Ar > C), 155.98 (N-CO), 169.71
(O-CO). IR (CCl4) ν max cm
−1 3437 w, 3322 w (NH); 2971 m, 2887
m, 1380 m, 1370 m (CH3); 2945 m, 2856 m (CH2); 1727 vs+vbr
(CO) all carbonyles; 1505 s (amide II); 3068 w, 3042 w, 3021 w,
1600 m, 1478 m, 1452 m, 678 s (ring). HRMS (ESI) calcd for
C26H31O6NNa [M + Na]
+ 476.204, found: 476.204.
Cell Cultures. Human IM-9 lymphocytes and NIH/3T3 mouse
ﬁbroblasts were obtained from ATCC. Mouse ﬁbroblasts derived from
IGF-1R knockout mice73 and stably transfected with either human
IGF-1 receptor (IGF-1R), or human insulin receptor isoform A (IR-
A), were kindly provided by Professor A. Belﬁore (University of
Magna Grecia, Catanzaro, Italy) and Professor R. Baserga (Thomas
Jeﬀerson University, Philadelphia, Pennsylvania, USA). IM-9 cells were
grown in RPMI 1640 media with 10% fetal bovine serum. IGF-1R and
IR-A cells were grown in DMEM media with 5 mM glucose with 10%
fetal bovine serum and 0.3 μg/mL puromycin. NIH/3T3 cells were
grown in DMEM media with 10% bovine serum albumin. All media
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were further supplemented with 2 mM L-glutamine, 100 U/mL
penicillin and 100 μg/mL streptomycin, and the cells were grown in
humidiﬁed air with 5% CO2 at 37 °C.
Receptor-Binding Studies. Human IM-9 Lymphocytes (Human
IR-A Isoform). Receptor-binding studies with the insulin receptor in
membranes of human IM-9 lymphocytes (containing only human IR-
A isoform) were performed and Kd values determined as described
previously.12,43 Binding data were analyzed using the Excel algorithms
speciﬁcally developed for the IM-9 cells system in the laboratory of
Prof. Pierre De Meyts (A. V. Groth and R. M. Shymko, Hagedorn
Research Institute, Denmark, a kind gift from P. De Meyts), using the
method of a non-linear regression, and a one-site ﬁtting program,
taking into account the potential depletion of the free ligand. Each
binding curve was determined in duplicate, and the ﬁnal dissociation
constant (Kd) of an analog was calculated from at least three (n ≥ 3)
binding curves (Kd values), determined independently. The dissoci-
ation constant of human 125I-insulin (PerkinElmer) was set to 0.3 nM.
Mouse Embryonic Fibroblasts (Human IGF-1R). Receptor binding
studies with the human IGF-1 receptor in membranes of mouse
embryonic ﬁbroblasts derived from IGF-1R knockout mice and
transfected with human IGF-1R were performed as described
previously.12,43 Binding data were analyzed, and the dissociation
constant (Kd) was determined with GraphPad Prism 5 software, using
a non-linear regression method and a one-site ﬁtting program, taking
into account potential depletion of free ligand. Each binding curve was
determined in duplicate, and the ﬁnal dissociation constant (Kd) of an
analogue was calculated from at least three (n ≥ 3) binding curves (Kd
values) determined independently. The dissociation constant of
human 125I-IGF-1 (PerkinElmer) was set to 0.2 nM. Here we should
note that the use of bovine serum albumin (e.g., Sigma-Aldrich A6003)
void of “IGF-binding-like” proteins, which interfere with these binding
assays, is essential for the preparation of the binding buﬀer.74
The signiﬁcance of the changes in binding aﬃnities of the analogs,
related to the binding of IGF-1, was calculated using a two-tailed t test.
Receptor Phosphorylation Assay. Cell Stimulation and
Detection of Receptor phosphorylation. Both were performed as
previously described.55 In brief, mouse ﬁbroblasts (NIH/3T3, IR-A
and IGF-1R) were seeded in 24-well plates (Schoeller) and incubated
for 24 h. Cells were afterward starved for 4 h in serum-free media. The
cells were stimulated with 10 nM concentrations of the ligands for 10
min. Proteins were routinely analyzed, using immunoblotting and
horseradish peroxidase-labeled secondary antibodies (Sigma-Aldrich).
The membranes were probed with antiphospho-IGF-1Rβ (Tyr1135/
1136)/IRβ (Tyr1150/1151) and antiphospho-Akt (Thr308)
(C31E5E) (Cell Signaling Technology). The blots were developed
using the SuperSignal West Femto maximum sensitivity substrate
(Pierce) and analyzed using the ChemiDoc MP Imaging System (Bio-
Rad). Each experiment was repeated four times. The data were
expressed as contribution of phosphorylation relatively to the human
insulin (IR-A) respective IGF-1 (NIH/3T3 and IGF-1R) signal. The
signiﬁcance of the changes in stimulation of phosphorylation of
receptors and related Akt-stimulation by the IGF-1 was calculated
using one-way analysis of variance.
Ligand-Dose Response IGF-1R Autophosphorylation Levels. The
levels were determined using In-Cell Western assay75 adapted for
chemiluminescence. The IGF-1R cells were plated at 20 000 cells/well
in white 96-well Brand plates cell grade (Brand GMBH, Germany) and
incubated for 24 h. Cells were afterward starved for 4 h in serum-free
media and stimulated with dilutions of ligands (0−100 nM) for 10
min. After incubation, the medium was discarded, and the cells were
ﬁxed in 3.75% freshly prepared formaldehyde for 20 min. Cells were
permeabilized with 0.1% Triton-X-100 in PBS for 5 min and blocked
with 5% BSA in T-TBS for 1 h. Plates were incubated with
antiphospho-IGF-1Rβ (Tyr1135/1136)/IRβ (Tyr1150/1151) over-
night at 4 °C. Then plates were thoroughly washed with TBS,
incubated with peroxidase-labeled antirabbit secondary antibody
(Sigma) for 1 h at room temperature, and washed again. SuperSignal
West Femto maximum sensitivity substrate was added to each well,
and chemiluminescence was detected using the ChemiDoc MP
Imaging System after 5 min. Data were subtracted from background
values and expressed as contribution of phosphorylation relatively to
the 10 nM IGF-1 signal. Control wells and wells stimulated with 10
nM IGF-1 were in tetraplicates on each plate. Experiments were
repeated at least four times. Log(agonist) vs response curve ﬁtting of
data was carried out with GraphPad Prism 5 software.
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